Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.33 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.33 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.32 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.32 |
| ▸ | ITGAV | P06756 | 1/20 | 0.32 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.32 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.32 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.32 |
| ▸ | ITGAL | P20701 | 1/20 | 0.32 |
| ▸ | CTSD | P07339 | 2/20 | 0.32 |
| ▸ | PRKCA | P17252 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.30 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31048256 | 1.00 | CREBBP (0.36) | CREBBPCRBNFKBP5ITGB3ITGB2 | |
| SCHEMBL4381020 | 0.94 | — | — | |
| SCHEMBL2999352 | 0.94 | — | — | |
| SCHEMBL5026514 | 0.94 | — | — | |
| SCHEMBL210597 | 0.85 | — | — | |
| SCHEMBL223376 | 0.85 | — | — | |
| SCHEMBL210598 | 0.85 | — | — | |
| SCHEMBL2989773 | 0.84 | IRAK4 (0.32) | CRBNFKBP5ITGB3ITGB2ITGB1 | |
| SCHEMBL4019894 | 0.83 | CRBN (0.36) | CRBNFKBP5ITGB3ITGB2ITGB1 | |
| SCHEMBL29742940 | 0.81 | KMT2A (0.35) | CRBNFKBP5CTSDCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-5086034-A | — | — | None | — | — | JP | disclosed |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2010-12-16 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-7790710-B2 | Imidazopyridine derivatives useful as iNOS inhibitors | NYCOMED GMBH (DE) | 2010-09-07 | — | — | US | disclosed |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2010-09-02 | — | — | US | disclosed |
| US-20100184770-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-07-22 | — | — | US | disclosed |
| EP-2205585-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | Glaxo Group Limited (GB) | 2010-07-14 | — | — | EP | disclosed |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NYCOMED GMBH (DE) | 2009-05-21 | — | — | US | disclosed |
| WO-2009050204-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | WO | disclosed |
| WO-2008074803-A2 | 4-BENZYL-L ( 2H) -PHTHALAZINONES AS H1 RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008031788-A1 | AMINOAZEPINE DERIVATIVES AS HIGHLY EFFICIENT INHIBITORS OF THE INDUCIBLE NITRIC OXIDE SYNTHASE | NYCOMED GMBH (DE) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008031788-A1 | AMINOAZEPINE DERIVATIVES AS HIGHLY EFFICIENT INHIBITORS OF THE INDUCIBLE NITRIC OXIDE SYNTHASE | NYCOMED GMBH (DE) | 2008-03-20 | — | — | WO | disclosed |
| EP-1866306-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | Nycomed GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006103255-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NYCOMED GMBH (DE) | 2006-10-05 | — | — | WO | disclosed |
| JP-H0586034-A | HYDROXYL GROUP-CONTAINING LACTAM DERIVATIVE AND ITS PRODUCTION | NIPPON OIL & FATS CO LTD | 1993-04-06 | — | — | JP | disclosed |
| US-4013625-A | Process for the linearization of polyurethanes with lactams and lactam addition compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-22 | — | — | US | disclosed |
| US-3968104-A | SOLVENTS | BAYER AKTIENGESELLSCHAFT (DT) | 1976-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317650-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS INOS INHIBITORS | NOS2, NOS1, ARG1 | CREBBP 1477/4885CRBN 2793/4885FKBP5 1950/4885 |
| US-20090131399-A1 | Imidazopyridine Derivatives Useful as iNOS Inhibitors | NOS2, NOS1, ARG1 | CREBBP 1477/4885CRBN 2793/4885FKBP5 1950/4885 |
| US-20100184770-A1 | COMPOUNDS | CMA1, TSLP, IL5 | CREBBP 2075/4885CRBN 1723/4885FKBP5 596/4885 |
| US-20100222349-A1 | QUINOLINE DERIVATIVES USED TO TREAT INFLAMMATORY AND ALLERGIC DISEASES | IL5, HRH2, HRH1 | CREBBP 1879/4885CRBN 2355/4885FKBP5 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.